FENC - Fennec Pharmaceuticals Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
9.11
-0.22 (-2.36%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close9.33
Open9.33
Bid8.30 x 600
Ask9.60 x 1000
Day's Range9.11 - 9.49
52 Week Range7.55 - 13.95
Volume28,729
Avg. Volume20,239
Market Cap167.728M
Beta-0.58
PE Ratio (TTM)N/A
EPS (TTM)-0.41
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 months ago

    Fennec Announces Closing of Public Offering

    RESEARCH TRIANGLE PARK, N.C., Dec. 12, 2017-- Fennec Pharmaceuticals Inc., a biotechnology company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity from cisplatin ...

  • American City Business Journals2 months ago

    Fennec’s $20M offering primes company for 2019 commercial launch

    “The proceeds are slated to be used to put us in a strong financial position as we go through 2018, which will be our filing year for approval,” says Chief Financial Officer Robert Andrade. As of Sept. 30, Fennec had about $9.7 million in cash, including $7.6 million it raised back in June.

  • GlobeNewswire2 months ago

    Fennec Announces Pricing of Public Offering

    RESEARCH TRIANGLE PARK, N.C., Dec. 08, 2017-- Fennec Pharmaceuticals Inc., a biotechnology company focused on the development of PEDMARK TM for the prevention of platinum-induced ototoxicity from cisplatin ...

  • GlobeNewswire2 months ago

    Fennec Announces Proposed Public Offering of Common Shares

    RESEARCH TRIANGLE PARK, N.C., Dec. 07, 2017-- Fennec Pharmaceuticals Inc., a biotechnology company focused on the development of PEDMARK™ for the prevention of platinum-induced ototoxicity from cisplatin ...

  • American City Business Journals4 months ago

    Fennec banks positive results on heels of move to Nasdaq

    On the heels of making its Nasdaq debut – moving from an over-the-counter market it started trading on several years ago – Research Triangle Park-based Fennec Pharmaceuticals (FENC) has banked positive Phase 3 results for its product for the prevention of hearing loss in pediatric cancer patients receiving chemotherapy. The Phase 3 results – for Fennec’s sodium thiosulfate therapy called PEDMARK – were presented at the International Society of Pediatric Oncology (SIOP) 2017 meeting over the weekend in Washington, D.C. They showed “significant improvement in the prevention of hearing loss” in children receiving PEDMARK with chemotherapy over those receiving chemotherapy alone, says Fennec Chief Financial Officer Robert Andrade. “A little bit of hearing loss is a big deal,” says Andrade, noting the impact Fennec envisions PEDMARK continuing to make for pediatric cancer patients.

  • Newsfile5 months ago

    IIROC Trade Resumption - Fennec Pharmaceuticals Inc.

    Toronto, Ontario--(Newsfile Corp. - September 13, 2017) - Trading resumes in: Company: Fennec Pharmaceuticals Inc. TSX Symbol: FRX (all issues) ...

  • Newsfile5 months ago

    IIROC Trade Halt - Fennec Pharmaceuticals Inc.

    Toronto, Ontario--(Newsfile Corp. - September 13, 2017) - The following issues have been halted by IIROC: Company:  Fennec Pharmaceuticals Inc. TSX Symbol: FRX (all issues) ...